Roche Drug Candidate Will Have Role in Breast Cancer Treatment -- Market Talk

Dow Jones06-01

1343 GMT - Roche Holding's new breast-cancer drug will have a role for the treatment of the disease after an initial therapy like surgery, UBS analysts say. A presentation at the American Society of Clinical Oncology's annual meeting reaffirmed that the drug, giredestrant, delivered benefit to patients compared to the current standard of care, even if it isn't yet clear where it should be used, UBS says. "We continue to think that giredestrant will have a role to play in the treatment of adjuvant therapy and that the lidERA study indicates it is a better and more tolerable option than currently used endocrine therapies for medium risk patients," the analysts say. Shares fall 2.3%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 01, 2026 09:43 ET (13:43 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640527109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640527109","market":"sh","top_or_hot":-1,"title":"Roche Drug Candidate Will Have Role in Breast Cancer Treatment -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1343 GMT - Roche Holding's new breast-cancer drug will have a role for the treatment of the disease after an initial therapy like surgery, UBS analysts say. A presentation at the American Society of Clinical Oncology's annual meeting reaffirmed that the drug, giredestrant, delivered benefit to patients compared to the current standard of care, even if it isn't yet clear where it should be used, UBS says. \"We continue to think that giredestrant will have a role to play in the treatment of adjuvant therapy and that the lidERA study indicates it is a better and more tolerable option than currently used endocrine therapies for medium risk patients,\" the analysts say. Shares fall 2.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 09:43 ET (13:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche Drug Candidate Will Have Role in Breast Cancer Treatment -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche Drug Candidate Will Have Role in Breast Cancer Treatment -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-01 21:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1343 GMT - Roche Holding's new breast-cancer drug will have a role for the treatment of the disease after an initial therapy like surgery, UBS analysts say. A presentation at the American Society of Clinical Oncology's annual meeting reaffirmed that the drug, giredestrant, delivered benefit to patients compared to the current standard of care, even if it isn't yet clear where it should be used, UBS says. \"We continue to think that giredestrant will have a role to play in the treatment of adjuvant therapy and that the lidERA study indicates it is a better and more tolerable option than currently used endocrine therapies for medium risk patients,\" the analysts say. Shares fall 2.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 01, 2026 09:43 ET (13:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHHBY","symbol_name":"罗氏控股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640527109","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640527109","pubTimestamp":1780321380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1343 GMT - Roche Holding's new breast-cancer drug will have a role for the treatment of the disease after an initial therapy like surgery, UBS analysts say. A presentation at the American Society of Clinical Oncology's annual meeting reaffirmed that the drug, giredestrant, delivered benefit to patients compared to the current standard of care, even if it isn't yet clear where it should be used, UBS says. \"We continue to think that giredestrant will have a role to play in the treatment of adjuvant therapy and that the lidERA study indicates it is a better and more tolerable option than currently used endocrine therapies for medium risk patients,\" the analysts say. Shares fall 2.3%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RHHBY":"罗氏控股","BK4007":"制药","03165":"华夏欧优股对冲"},"translate_title":"罗氏候选药物将在乳腺癌治疗中发挥作用——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"RHHBY":0.9},"content_text":"1343 GMT - Roche Holding's new breast-cancer drug will have a role for the treatment of the disease after an initial therapy like surgery, UBS analysts say. A presentation at the American Society of Clinical Oncology's annual meeting reaffirmed that the drug, giredestrant, delivered benefit to patients compared to the current standard of care, even if it isn't yet clear where it should be used, UBS says. \"We continue to think that giredestrant will have a role to play in the treatment of adjuvant therapy and that the lidERA study indicates it is a better and more tolerable option than currently used endocrine therapies for medium risk patients,\" the analysts say. Shares fall 2.3%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 09:43 ET (13:43 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640527109","isCrawlerRequest":true}